How Effective Is the Flu Vaccine? Year-by-Year Data and What It Means

Every flu season, the question comes up: "How effective is the flu vaccine this year?" The answer is never a single number — it changes from season to season, and even within a season, depending on which influenza strains are circulating, the age group being studied, and whether we're measuring protection against any infection or only severe illness. This article explains what flu vaccine effectiveness really means, what the historical data shows, and — most importantly — why vaccination remains one of the best tools we have, even in years when effectiveness against infection is relatively low.[1][2]

What Does "Vaccine Effectiveness" Actually Mean?

Vaccine effectiveness (VE) is a measure of how well the flu vaccine works in the real world — as opposed to vaccine efficacy, which is measured in controlled clinical trials. The CDC and other public health agencies calculate VE each season by comparing the odds of vaccination among people who test positive for flu (cases) versus people who test negative (controls). The formula:[1][3]

VE = (1 − Odds Ratio) × 100%

A VE of 40% means that vaccinated people had 40% fewer medically attended flu illnesses than unvaccinated people. It does not mean that 60% of vaccinated people got the flu — a common misinterpretation. It also does not mean the vaccine only "works" 40% of the time for each individual. It's a population-level measure of risk reduction.[3]

Historical Flu Vaccine Effectiveness: Year-by-Year Data (US)

The table below summarizes CDC estimates of flu vaccine effectiveness against medically attended influenza illness for recent US flu seasons. These numbers represent overall VE across all ages and virus types unless otherwise noted.[1][4]

Data sourced from CDC Flu VE Network studies and published estimates. Preliminary figures are subject to revision. Where ranges exist, a midpoint estimate is provided. H3N2-dominant seasons consistently show lower VE due to egg-adaptive mutations and faster antigenic drift of H3N2 viruses.[1][4]

Why Does Effectiveness Vary So Much?

Several factors determine how effective the flu vaccine will be in any given season:[2][5]

1. Match Between Vaccine Strains and Circulating Strains

This is the single biggest factor. The WHO selects vaccine strains in February (Northern Hemisphere) based on surveillance data — but flu viruses continue to evolve, and there's about a 6–9 month gap between strain selection and vaccine delivery. If the circulating strains "drift" genetically during that window, the match degrades. This is especially common with H3N2 viruses, which mutate faster than H1N1 or influenza B.[2]

2. Egg-Adaptive Mutations (H3N2 Problem)

Most flu vaccines are produced in chicken eggs — a method that dates back to the 1940s. When H3N2 viruses are grown in eggs, they often acquire mutations that make the resulting vaccine less effective against the wild-type virus circulating in humans. This is a major reason H3N2 VE is consistently lower. Newer technologies — cell-based vaccines (Flucelvax), recombinant vaccines (Flublok), and mRNA vaccines in development — aim to solve this problem by eliminating egg adaptation.[5]

3. Prior Vaccination and Immune History

Your immune system's prior encounters with flu — through both vaccination and natural infection — shape your response to each year's vaccine. In some seasons, people vaccinated in consecutive years may show slightly lower VE than those vaccinated only in the current year. However, cumulative protection from annual vaccination consistently reduces severe outcomes more than sporadic vaccination.[5]

4. Age and Immune Status

VE is typically highest in healthy adults aged 18–49 and lower in older adults (65+), whose immune systems respond less robustly. This is why enhanced vaccines — high-dose (Fluzone High-Dose), adjuvanted (Fluad), and recombinant (Flublok) — are specifically recommended for older adults. In studies, these enhanced vaccines boost VE by 10–30 percentage points in the 65+ population compared to standard-dose vaccines.[1][5]

VE Against Severe Outcomes Is Higher Than VE Against Any Infection

This is the most important point that most VE discussions miss. The flu vaccine performs substantially better against severe outcomes — hospitalization, ICU admission, and death — than against outpatient illness. Even in the worst-matched seasons, vaccination consistently reduces the risk of severe disease:[1][6]

Sources: CDC, Thompson MG et al. (2018) Vaccine, Flannery B et al. (2017) Pediatrics, Ferdinands JM et al. (2019) J Infect Dis.[1][6]

Is the Flu Vaccine Worth It in Low-Effectiveness Years?

This question comes up every H3N2-dominant season when VE drops to 20–30%. The short answer is yes — even in low-VE years, vaccination prevents substantial illness and death.[1][6]

Consider the math: a VE of 20% against illness in a season with 30 million flu cases still means 6 million prevented illnesses. At a population level, that translates to tens of thousands of prevented hospitalizations and thousands of prevented deaths — even in a "bad match" year.[6]

Furthermore, VE against hospitalization typically remains above 30% even when VE against all illness is at its lowest. The vaccine's protection against severe disease appears more robust against strain mismatch than its protection against mild illness — likely because the immune response required to prevent severe lower respiratory infection is less strain-specific than the response needed to prevent any upper respiratory infection.[5][6]

The Future: Better Vaccines Are Coming

The limitations of current egg-based vaccines have driven development of next-generation approaches:[2][5]

• mRNA flu vaccines (Moderna, Pfizer): mRNA technology enables faster vaccine production, eliminating egg-adaptive mutations and allowing later strain selection — potentially improving match quality. Clinical trials show promising immunogenicity.
• Universal flu vaccines: Researchers are pursuing vaccines targeting conserved regions of the influenza virus that don't change from year to year — the hemagglutinin "stem" rather than the variable "head." A universal vaccine could provide broad protection against multiple strains for years, eliminating the annual guessing game.
• Cell-based and recombinant vaccines (already available): Flucelvax (cell-based) and Flublok (recombinant) avoid egg adaptation entirely. Studies suggest they may provide 5–15 percentage points higher VE against H3N2 compared to egg-based vaccines in some seasons.